- Does Preschool Boost Kids’ Long-Term Academic Success? Study Finds Mixed Results
- AI Might Spot Rare Diseases in Patients Years Earlier
- An Orangutan Healed Himself With Medicinal Plant
- Quit-Smoking Meds Not Working for You? Try Upping the Dose
- Fewer Americans Are Suffering Most Dangerous Form of Heart Attack
- Even Skipping Meat for One Meal Helps Liver Disease Patients
- You May Not Have to Fast Before Catheter-Based Heart Test, Study Suggests
- EPA Earmarks $3 Billion to Replace Lead Pipes Nationwide
- Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits
- No Sign of Bird Flu in Ground Beef, USDA Says
ADHD Drug Zenzedi Recalled Over Pill Mixup
The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.
The recall notice, issued by Azurity Pharmaceuticals Inc., states that one lot of Zenzedi 30-milligram tablets is being recalled after a pharmacist found antihistamine tablets in a bottle labeled as Zenzedi.
The active compound in Zenzedi is dextroamphetamine sulfate, a stimulant used for the treatment of narcolepsy and ADHD. Meanwhile, the allergy drug found in the mislabeled bottles contains the sedative carbinoxamine, which has the opposite effect of a stimulant.
The recall comes amid an ongoing national shortage of ADHD drugs, creating further frustration for people with ADHD who have struggled to find medications for their condition, CNN reported.
The recall notice said that people who take carbinoxamine instead of Zenzedi have a higher risk of accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction and thyroid disorder. The recalled lot has the lot number F230169A and an expiration date of June 2025.
Azurity added that it has not received any reports of serious injury related to the medication mixup.
Consumers who have the recalled medication should return it to their pharmacy and call their doctor if they have any bad reactions to the drug.
Problems may also be reported to the FDA’s MedWatch Adverse Event Reporting program.
More information
Drugs.com has more on Zenzedi.
SOURCE: U.S. Food and Drug Administration, recall notice, Jan. 25, 2024
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.